| Trial ID: | L3035 |
| Source ID: | NCT01038648
|
| Associated Drug: |
Sitagliptin
|
| Title: |
Sitagliptin in Prevention of Type 2 Diabetes Mellitus
|
| Acronym: |
SITAGLIPTIN
|
| Status: |
WITHDRAWN
|
| Study Results: |
NO
|
| Results: |
|
| Conditions: |
Type 2 Diabetes
|
| Interventions: |
DRUG: Sitagliptin|OTHER: life style modification at base line
|
| Outcome Measures: |
Primary: 1. Rate of conversion of IGT to diabetes. 2. Relative reduction of incidence of diabetes by Sitagliptin among people with IGT compared to Placebo. 3. Increase in reversal of IGT to NGT, At intervals -6 months | Secondary: 1. Beneficial effects in beta cell function. 2. Changes in insulin resistance 3. Improvement in cardiovascular risk factors by Sitagliptin., Annual
|
| Sponsor/Collaborators: |
Sponsor: India Diabetes Research Foundation & Dr. A. Ramachandran's Diabetes Hospitals
|
| Gender: |
ALL
|
| Age: |
ADULT
|
| Phases: |
PHASE3
|
| Enrollment: |
0
|
| Study Type: |
INTERVENTIONAL
|
| Study Designs: |
Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: DOUBLE (PARTICIPANT, INVESTIGATOR)|Primary Purpose: PREVENTION
|
| Start Date: |
2011-12
|
| Completion Date: |
2014-12
|
| Results First Posted: |
|
| Last Update Posted: |
2015-12-30
|
| Locations: |
Dr.Ambady Ramachandran, Chennai, Tamil nadu, 600 008, India
|
| URL: |
https://clinicaltrials.gov/show/NCT01038648
|
